MBP and relapsing-remitting multiple sclerosis: Several independent laboratories have reported that untreated RRMS patients have elevated frequencies of PBMC that produce IFNγ or IL-17 in response to ex vivo challenges with human myelin basic protein (MBP), human proteolipid protein (PLP), or their constituent peptides [43,44,45,46].